[Articles] Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with obesity or overweight (VISTA): a multicentre, phase 2, randomised, placebo-controlled clinical trial

A phase 2 study investigated the effects of oral elecoglipron in adults with obesity or overweight. This drug is a small molecule GLP-1 receptor agonist, administered daily. The results demonstrated clinically meaningful weight reductions in participants. The safety and tolerability profile was consistent with other drugs belonging to the GLP-1 agonist class. This was a dose-ranging study aimed at determining appropriate dosages. The findings from this phase 2 support further investigation of elecoglipron in phase 3 studies. The goal is to confirm its efficacy and safety in people living with obesity or overweight. This suggests elecoglipron's potential as a new treatment option.